Denise Connolly, PhDFox Chase Cancer Center2015 Pape Family Pilot Award Sensitizing ovarian cancer to PARP inhibition PARP inhibitors are among the most promising class of targeted therapeutics for the treatment of ovarian cancer. Patients with mutations in BRCA genes and some patients with sporadic cancers are particularly sensitive to this class of drugs, presumably because […]
Read More
Erinn Rankin, PhDStanford University2016 Pape Family Pilot Study Award Targeting the hypoxic secretome in omental metastasis Mesothelial cells line the abdominal cavity and play an important role in ovarian cancer metastasis. These mesothelial cells in the presence of ovarian cancer tumors are deprived of oxygen (hypoxic) and, as a result, produce components of the hypoxia […]
Read More
Rosana Risques, PhDUniversity of Washington 2017 Pape Family Pilot Study Award Characterization of TP53 mutations in BRCA carcinogenesis Women with inherited mutations in the BRCA1 and BRCA2 genes have a greatly increased risk of developing high-grade serous ovarian cancer (HGSOC). This type of cancer starts as a lesion in the fallopian tube, and these lesions almost always contain cells […]
Read More